Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Kiadis Pharma Receives Regulatory Approval from Health Canada

Published: Thursday, February 28, 2013
Last Updated: Wednesday, February 27, 2013
Bookmark and Share
Company has received No Objection Letter for its new clinical study with ATIR™.

Kiadis Pharma B.V. has announced that it has received the No Objection Letter from Health Canada for its new clinical study with ATIR™.

This study will be a Phase II international multi-center study with clinical sites in Canada and Belgium.

Up to 23 patients will be treated in this study to corroborate and extend the safety and efficacy results from Kiadis Pharma‘s previous Phase I/II clinical study with ATIR™.

The coordinating investigator for the study will be Denis-Claude Roy, MD, professor of medicine at the University of Montreal. ATIR™ is a cell-based product designed to enable stem cell transplantations from mismatched (haploidentical) family donors.

“We are very happy that after having received approval from the Research Ethics Board of the Maisonneuve-Rosemont Hospital, we have now also gained approval from Health Canada and can commence with our new clinical study in Canada”, commented Manfred Ruediger, PhD, Chief Executive Officer of Kiadis Pharma.

Ruediger continued, “This study will be an important step forward in developing ATIR™ as an innovative therapeutic option for severely diseased blood cancer patients. Today, many of these patients die because a matched stem cell donor cannot be found.”

Dr. Denis-Claude Roy added: “We are excited that we can start this Phase II clinical study with ATIR™ in which we will treat blood cancer patients for whom a matched donor is not available for a standard transplantation procedure. This study provides these patients with the opportunity to receive a stem cell transplantation from a family member with ATIR™ added as an adjunctive treatment to provide rapid and potent immune protection and minimize post-transplant risks.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Kiadis Pharma Completes Five-year Follow-up of its Phase I/II Clinical Study with Blood Cancer Product ATIR™
67% survival demonstrated after 5 years and no transplant related mortalities.
Tuesday, September 17, 2013
Kiadis Pharma Granted U.S. Patent for its Blood Cancer Treatment ATIR™
ATIR™ is a cell-based product that enables stem cell transplantations from mismatched donors.
Monday, January 21, 2013
Scientific News
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
Defining Immortality of Stem Cells
Researchers defined the mechanisms underlying increased protein quality control of pluripotent stem cells.
Enhancing CRISPR to Explore Further
Researchers have developed sOPTiKO, a more efficient and controllable CRISPR genome editing platform.
Regenerating Diseased Hearts
Researchers from the University of Otago have probed the potential of adult stem cell types to repair diseased hearts.
Stem Cells Police Themselves to Reduce Scarring
Scientists have discovered stem cells in muscle fibers change gene expressions to respond to injury.
Bright Red Fluorescent Protein Created
Scientists have created a bright red, fluorescent protein that could be used to track essential cellular processes.
Protein Self-Regulates Abundance
Researchers have uncovered how a protein, that plays a crucial role in embryonic stem cell renewal, is regulated.
Topical Immunotherapy Effective Against Early Skin Cancer
Combination of two commonly used drugs triggers immune response against precancerous skin lesions.
Factors Behind Suppression of Stem Cell Mobilization Revealed
The findings could lead to improvements in transplantation therapy.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!